Bristol-Myers Squibb (BMY) Nivolumab Shows Objective Response Rate of 15% in CheckMate -063 Study
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE